Vpu Augments the Initial Burst Phase of HIV-1 Propagation and Downregulates BST2 and CD4 in Humanized Mice

ABSTRACT While human cells express potent antiviral proteins as part of the host defense repertoire, viruses have evolved their own arsenal of proteins to antagonize them. BST2 was identified as an inhibitory cellular protein of HIV-1 replication, which tethers virions to the cell surface to prevent their release. On the other hand, the HIV-1 accessory protein, Vpu, has the ability to downregulate and counteract BST2. Vpu also possesses the ability to downmodulate cellular CD4 and SLAMF6 molecules expressed on infected cells. However, the role of Vpu in HIV-1 infection in vivo remains unclear. Here, using a human hematopoietic stem cell-transplanted humanized mouse model, we demonstrate that Vpu contributes to the efficient spread of HIV-1 in vivo during the acute phase of infection. Although Vpu did not affect viral cytopathicity, target cell preference, and the level of viral protein expression, the amount of cell-free virions in vpu-deficient HIV-1-infected mice was profoundly lower than that in wild-type HIV-1-infected mice. We provide a novel insight suggesting that Vpu concomitantly downregulates BST2 and CD4, but not SLAMF6, from the surface of infected cells. Furthermore, we show evidence suggesting that BST2 and CD4 impair the production of cell-free infectious virions but do not associate with the efficiency of cell-to-cell HIV-1 transmission. Taken together, our findings suggest that Vpu downmodulates BST2 and CD4 in infected cells and augments the initial burst of HIV-1 replication in vivo. This is the first report demonstrating the role of Vpu in HIV-1 infection in an in vivo model.

[1]  R. Lamb,et al.  Influenza virus is not restricted by tetherin whereas influenza VLP production is restricted by tetherin. , 2011, Virology.

[2]  Y. Koyanagi,et al.  The mouse is out of the bag: insights and perspectives on HIV-1-infected humanized mouse models , 2011, Experimental biology and medicine.

[3]  Mamoru Ito,et al.  A novel animal model of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in humanized mice. , 2011, Blood.

[4]  K. Strebel,et al.  The interferon-inducible host factor bone marrow stromal antigen 2/tetherin restricts virion release, but is it actually a viral restriction factor? , 2011, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[5]  G. Nemerow,et al.  Functional Genetic and Biophysical Analyses of Membrane Disruption by Human Adenovirus , 2011, Journal of Virology.

[6]  M. Wainberg,et al.  Tetherin restricts direct cell-to-cell infection of HIV-1 , 2010, Retrovirology.

[7]  E. Campbell,et al.  Degranulation of natural killer cells following interaction with HIV-1-infected cells is hindered by downmodulation of NTB-A by Vpu. , 2010, Cell host & microbe.

[8]  Takeshi Yoshida,et al.  Identification of Amino Acids in the Human Tetherin Transmembrane Domain Responsible for HIV-1 Vpu Interaction and Susceptibility , 2010, Journal of Virology.

[9]  Jinhong Chang,et al.  Interferon-Induced Cell Membrane Proteins, IFITM3 and Tetherin, Inhibit Vesicular Stomatitis Virus Infection via Distinct Mechanisms , 2010, Journal of Virology.

[10]  Clare Jolly,et al.  Cell-Cell Spread of Human Immunodeficiency Virus Type 1 Overcomes Tetherin/BST-2-Mediated Restriction in T cells , 2010, Journal of Virology.

[11]  Rajendra Singh,et al.  BST-2/tetherin: a new component of the innate immune response to enveloped viruses. , 2010, Trends in microbiology.

[12]  G. Ruthel,et al.  Infectious Lassa Virus, but Not Filoviruses, Is Restricted by BST-2/Tetherin , 2010, Journal of Virology.

[13]  F. Kirchhoff Immune evasion and counteraction of restriction factors by HIV-1 and other primate lentiviruses. , 2010, Cell host & microbe.

[14]  Mamoru Ito,et al.  Remarkable Lethal G-to-A Mutations in vif-Proficient HIV-1 Provirus by Individual APOBEC3 Proteins in Humanized Mice , 2010, Journal of Virology.

[15]  P. Cannon,et al.  HIV-1 Vpu and HIV-2 Env counteract BST-2/tetherin by sequestration in a perinuclear compartment , 2010, Retrovirology.

[16]  O. Schwartz,et al.  Tetherin Restricts Productive HIV-1 Cell-to-Cell Transmission , 2010, PLoS pathogens.

[17]  Mamoru Ito,et al.  Dynamics of memory and naïve CD8+ T lymphocytes in humanized NOD/SCID/IL-2Rgammanull mice infected with CCR5-tropic HIV-1. , 2010, Vaccine.

[18]  A. Moses,et al.  The Great Escape: Viral Strategies to Counter BST-2/Tetherin , 2010, PLoS pathogens.

[19]  P. Bieniasz,et al.  The RING-CH Ligase K5 Antagonizes Restriction of KSHV and HIV-1 Particle Release by Mediating Ubiquitin-Dependent Endosomal Degradation of Tetherin , 2010, PLoS pathogens.

[20]  F. Kirchhoff,et al.  Vpu serine 52 dependent counteraction of tetherin is required for HIV-1 replication in macrophages, but not in ex vivo human lymphoid tissue , 2010, Retrovirology.

[21]  Mamoru Ito,et al.  Selective infection of CD4+ effector memory T lymphocytes leads to preferential depletion of memory T lymphocytes in R5 HIV-1-infected humanized NOD/SCID/IL-2Rgammanull mice. , 2009, Virology.

[22]  G. Learn,et al.  Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains. , 2009, Cell host & microbe.

[23]  S. Neil,et al.  Antagonism to and Intracellular Sequestration of Human Tetherin by the Human Immunodeficiency Virus Type 2 Envelope Glycoprotein , 2009, Journal of Virology.

[24]  Marc C. Johnson,et al.  Nef proteins from simian immunodeficiency viruses are tetherin antagonists. , 2009, Cell host & microbe.

[25]  A. Moses,et al.  Molecular Mechanism of BST2/Tetherin Downregulation by K5/MIR2 of Kaposi's Sarcoma-Associated Herpesvirus , 2009, Journal of Virology.

[26]  A. Moses,et al.  Vpu Directs the Degradation of the Human Immunodeficiency Virus Restriction Factor BST-2/Tetherin via a βTrCP-Dependent Mechanism , 2009, Journal of Virology.

[27]  Takeshi Yoshida,et al.  Comparative study on the effect of human BST-2/Tetherin on HIV-1 release in cells of various species , 2009, Retrovirology.

[28]  S. Westmoreland,et al.  Species-Specific Activity of SIV Nef and HIV-1 Vpu in Overcoming Restriction by Tetherin/BST2 , 2009, PLoS pathogens.

[29]  R. Benarous,et al.  Vpu Antagonizes BST-2–Mediated Restriction of HIV-1 Release via β-TrCP and Endo-Lysosomal Trafficking , 2009, PLoS pathogens.

[30]  H. Kräusslich,et al.  HIV-1 antagonism of CD317 is species specific and involves Vpu-mediated proteasomal degradation of the restriction factor. , 2009, Cell host & microbe.

[31]  Q. Sattentau,et al.  Cell-to-cell HIV-1 spread and its implications for immune evasion , 2009, Current opinion in HIV and AIDS.

[32]  P. Bates,et al.  Tetherin-mediated restriction of filovirus budding is antagonized by the Ebola glycoprotein , 2009, Proceedings of the National Academy of Sciences.

[33]  K. Strebel,et al.  Vpu enhances HIV-1 virus release in the absence of Bst-2 cell surface down-modulation and intracellular depletion , 2009, Proceedings of the National Academy of Sciences.

[34]  T. Noda,et al.  Inhibition of Lassa and Marburg Virus Production by Tetherin , 2008, Journal of Virology.

[35]  P. Bieniasz,et al.  Broad-Spectrum Inhibition of Retroviral and Filoviral Particle Release by Tetherin , 2008, Journal of Virology.

[36]  Q. Sattentau,et al.  Avoiding the void: cell-to-cell spread of human viruses , 2008, Nature Reviews Microbiology.

[37]  Marc C. Johnson,et al.  The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. , 2008, Cell host & microbe.

[38]  P. Bieniasz,et al.  Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu , 2008, Nature.

[39]  Yuetsu Tanaka,et al.  Modulation of Human Immunodeficiency Virus Type 1 Infectivity through Incorporation of Tetraspanin Proteins , 2007, Journal of Virology.

[40]  Q. Sattentau,et al.  Regulated secretion from CD4+ T cells. , 2007, Trends in immunology.

[41]  Q. Sattentau,et al.  Adhesion Molecule Interactions Facilitate Human Immunodeficiency Virus Type 1-Induced Virological Synapse Formation between T Cells , 2007, Journal of Virology.

[42]  W. Sundquist,et al.  An interferon-alpha-induced tethering mechanism inhibits HIV-1 and Ebola virus particle release but is counteracted by the HIV-1 Vpu protein. , 2007, Cell host & microbe.

[43]  Q. Sattentau,et al.  Human Immunodeficiency Virus Type 1 Assembly, Budding, and Cell-Cell Spread in T Cells Take Place in Tetraspanin-Enriched Plasma Membrane Domains , 2007, Journal of Virology.

[44]  Clare Jolly,et al.  Requirement for an Intact T-Cell Actin and Tubulin Cytoskeleton for Efficient Assembly and Spread of Human Immunodeficiency Virus Type 1 , 2007, Journal of Virology.

[45]  B. Blom,et al.  Use of a Novel Chimeric Mouse Model with a Functionally Active Human Immune System To Study Human Immunodeficiency Virus Type 1 Infection , 2007, Clinical and Vaccine Immunology.

[46]  P. Bieniasz,et al.  HIV-1 Vpu Promotes Release and Prevents Endocytosis of Nascent Retrovirus Particles from the Plasma Membrane , 2006, PLoS pathogens.

[47]  Q. Sattentau,et al.  Human Immunodeficiency Virus Type 1 Virological Synapse Formation in T Cells Requires Lipid Raft Integrity , 2005, Journal of Virology.

[48]  Q. Sattentau,et al.  Retroviral Spread by Induction of Virological Synapses , 2004, Traffic.

[49]  P. Spearman,et al.  Viral protein U counteracts a human host cell restriction that inhibits HIV-1 particle production , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[50]  F. Kirchhoff,et al.  Enhanced CD4 Down-modulation by Late Stage HIV-1 nef Alleles Is Associated with Increased Env Incorporation and Viral Replication* , 2003, Journal of Biological Chemistry.

[51]  É. Cohen,et al.  Vpu Exerts a Positive Effect on HIV-1 Infectivity by Down-modulating CD4 Receptor Molecules at the Surface of HIV-1-producing Cells* , 2003, Journal of Biological Chemistry.

[52]  Mamoru Ito,et al.  NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. , 2002, Blood.

[53]  J. Kappes,et al.  Emergence of Resistant Human Immunodeficiency Virus Type 1 in Patients Receiving Fusion Inhibitor (T-20) Monotherapy , 2002, Antimicrobial Agents and Chemotherapy.

[54]  F. Wong-Staal,et al.  Cell Surface CD4 Interferes with the Infectivity of HIV-1 Particles Released from T Cells* , 2002, The Journal of Biological Chemistry.

[55]  Peng Li,et al.  Rapid and efficient cell-to-cell transmission of human immunodeficiency virus infection from monocyte-derived macrophages to peripheral blood lymphocytes. , 1999, Virology.

[56]  D. Trono,et al.  Cell-surface expression of CD4 reduces HIV-1 infectivity by blocking Env incorporation in a Nef- and Vpu-inhibitable manner , 1999, Current Biology.

[57]  B. Cullen,et al.  Inhibition of HIV-1 progeny virion release by cell-surface CD4 is relieved by expression of the viral Nef protein , 1999, Current Biology.

[58]  U. Schubert,et al.  Regulation of Virus Release by the Macrophage-Tropic Human Immunodeficiency Virus Type 1 AD8 Isolate Is Redundant and Can Be Controlled by either Vpu or Env , 1999, Journal of Virology.

[59]  D. Thomas,et al.  A novel human WD protein, h-beta TrCp, that interacts with HIV-1 Vpu connects CD4 to the ER degradation pathway through an F-box motif. , 1998, Molecular cell.

[60]  J. Yewdell,et al.  CD4 Glycoprotein Degradation Induced by Human Immunodeficiency Virus Type 1 Vpu Protein Requires the Function of Proteasomes and the Ubiquitin-Conjugating Pathway , 1998, Journal of Virology.

[61]  A. Barrett,et al.  Attenuation of Japanese encephalitis virus by selection of its mouse brain membrane receptor preparation escape variants. , 1998, Virology.

[62]  J. Kira,et al.  Mutational analysis of human immunodeficiency virus type 1 (HIV-1) accessory genes: requirement of a site in the nef gene for HIV-1 replication in activated CD4+ T cells in vitro and in vivo , 1997, Journal of virology.

[63]  M. Martin,et al.  Construction and characterization of a stable full-length macrophage-tropic HIV type 1 molecular clone that directs the production of high titers of progeny virions. , 1996, AIDS research and human retroviruses.

[64]  U. Schubert,et al.  The two biological activities of human immunodeficiency virus type 1 Vpu protein involve two separable structural domains , 1996, Journal of virology.

[65]  U. Schubert,et al.  Augmentation of virus secretion by the human immunodeficiency virus type 1 Vpu protein is cell type independent and occurs in cultured human primary macrophages and lymphocytes , 1995, Journal of virology.

[66]  F. Maldarelli,et al.  Human immunodeficiency virus type 1 Vpu protein is an oligomeric type I integral membrane protein , 1993, Journal of virology.

[67]  W. Haseltine,et al.  Vpu protein of human immunodeficiency virus type 1 enhances the release of capsids produced by gag gene constructs of widely divergent retroviruses. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[68]  M. Martin,et al.  Human immunodeficiency virus type 1 Vpu protein induces rapid degradation of CD4 , 1992, Journal of virology.

[69]  D. Dimitrov,et al.  Cell-to-cell spread of HIV-1 occurs within minutes and may not involve the participation of virus particles. , 1992, Virology.

[70]  T. Klimkait,et al.  A novel gene of HIV-1, vpu, and its 16-kilodalton product. , 1988, Science.

[71]  Mamoru Ito,et al.  Interleukin-4-transgenic hu-PBL-SCID mice: a model for the screening of antiviral drugs and immunotherapeutic agents against X4 HIV-1 viruses. , 2008, The Journal of infectious diseases.

[72]  A. Finzi,et al.  Role of CD4 receptor down-regulation during HIV-1 infection. , 2004, Current HIV research.

[73]  Mamoru Ito,et al.  NOD / SCID / cnull mouse : an excellent recipient mouse model for engraftment of human cells , 2002 .